Measuring disease progression in early parkinson disease the national institutes of health exploratory trials in parkinson disease (NET-PD) experience

JAMA Neurology

Volumn 71, Issue 6, 2014, Pages 710-716

  Parashos, Sotirios A ^a   Luo, Sheng ^b   Biglan, Kevin M ^c   Bodis Wollner, Ivan ^d   Liang, Grace S ^e   Ross, G Webster ^f   Tilley, Barbara C ^b   Shulman, Lisa M ^g  

^a Struthers Parkinson's Center   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e PARKINSON S INSTITUTE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; GPI 1485; MINOCYCLINE; PLACEBO; UBIDECARENONE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; EDUCATIONAL STATUS; FEMALE; FUNCTIONAL STATUS; HAZARD RATIO; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RATING SCALE; SCORING SYSTEM; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); PARKINSON DISEASE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; UNITED STATES;

EID: 84902147760     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.391     Document Type: Article

References (19)

1. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G,WeinerWJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):968-975
2. Parashos SA, Maraganore DM, O'Brien PC, Rocca WA. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc. 2002;77(9):918-925 (Pubitemid 34977634)
3. Elm JJ, Goetz CG, Ravina B, et al NET-PD Investigators. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005;57(2):197-203
4. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66(5):664-671
5. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68(1):20-28
6. Parashos SA, Swearingen CJ, Biglan KM, et al NET-PD Investigators. Determinants of the timing of symptomatic treatment in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol. 2009;66(9):1099-1104
7. Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CO, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Health Care Information; 1987:153-164
8. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607
9. Schwab RS, England ACJ. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson's Disease, held at the Royal College of Surgeons of Edinburgh on 20, 21 and 22 May 1968. Edinburgh, Scotland: E & S Livingstone; 1969:152-157
10. Shoulson I, Kurlan R, Rubin A, et al. Assessment of functional capacity in neurodegenerative disorders: Huntington's disease as a prototype. In: Munsat TL, ed. Quantification of Neurologic Deficit. Waltham, MA: Butterworth- Heinemann; 1989: 285-309
11. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing. 1997;26(5):353-357 (Pubitemid 27448379)
12. Ware JE Jr, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-12 Health Survey (With a Supplement Documenting Version 1). Lincoln, RI: QualityMetric Inc; 2002
13. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321(20):1364-1371
14. Dafni UG, Tsiatis AA. Evaluating surrogate markers of clinical outcome when measured with error. Biometrics. 1998;54(4):1445-1462 (Pubitemid 29018627)
15. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley; 1989
16. Grambsch P, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526. doi:10 .1093/biomet/81.3.515
17. McDermottMP, Jankovic J, Carter J, et al; The Parkinson Study Group. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. Arch Neurol. 1995;52(6): 565-570
18. Marras C, McDermottMP, Marek K, et al; Parkinson Study Group DATATOP and PRECEPT investigators. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord. 2011;26(4):608-613
19. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The evolution of disability in Parkinson disease. Mov Disord. 2008;23(6):790-796.